COMPANY

Auron Therapeutics

HQ: Newton, MA source · aurontx.com ↗ · New England

We are developing a portfolio that is the direct output of our AURIGIN platform. From company website Source · Oct 12, 2026

Keywords: dermatology respiratory Relapsed Acute Myeloid Leukemia (AML) Refractory Acute Myeloid Leukemia (AML) Relapsed/Refractory AML Relapsed Myelodysplastic Syndromes Refractory Myelodysplastic Syndromes Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) AUTX-703

Location: Newton, MA · source · Oct 15, 2026

Profile checked Oct 10, 2026

$27.0MRaised (2 yrs)1Trials (company is sponsor)

Funding and NIH signals

SEC Form D raise Raised $7.12M in debt securities (Form D filed Aug 13, 2026). SEC Form D 0001746139-26-000002 (Aug 13, 2026)
Evidence (1 event)
- Aug 13, 2026 · SEC Form D 0001746139-26-000002
  Name of Issuer: Auron Therapeutics, Inc.; CIK: 1746139; Address: Wellesley, MA; Submission type: D; Filing date: 2026-08-13; Industry Group: Biotechnology; Date of First Sale: 2026-08-10; Types of Securities Offered: Debt; Business combination transaction: false; Total Offering Amount: 12000000; Total Amount Sold: 7118141; Federal exemptions: 06b

Job counts as of Oct 18, 2026. All funding and NIH signals

Raises and deals from press releases

Raise Series B · $27M · announced Feb 4, 2025 Company release ↗
Source quote
- Feb 4, 2025 · Company release ↗
  “– Auron … Therapeutics , a clinical-stage biotechnology company targeting cell-state plasticity to improve patient outcomes in oncology and inflammatory disease, today announced progress for its lead KAT2A/B program and clinical candidate, AUTX-703, and the completion of a $27 million Series B fina”

Raises announced in these releases: $27M disclosed.

From the company’s own releases; this list is partial. All raises and deals

Timeline

May 1, 2025 Trial start 1: Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS source ↗
Feb 4, 2025 Raise Private equity round — Series B: $27M (total, as published), announced Feb 4, 2025. Source: company's own press page. source ↗
Feb 4, 2025 Raise Series B · $27M source ↗

Upcoming milestones

2027-04 (ESTIMATED) · 1 · Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS · NCT06846606

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $27.0M. Last 2 years.

Feb 4, 2025 Private equity round — Series B: $27M (total, as published), announced Feb 4, 2025. Source: company's own press page. source ↗

Clinical trials (lead sponsor) 1

Record	Title	Phase	Status	Start	Primary completion
NCT06846606	Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS	1	Recruiting	May 1, 2025	2027-04 (estimated)